Everstone Capital

Everstone acquires controlling stake in Softgel Healthcare | Everstone Group

Headquartered in Chennai, SHPL is part of the Madras Pharma Group, a leading pharmaceutical contract manufacturing organization in southern India, with 8 manufacturing facilities covering all dosage forms. SHPL specializes in research, development and manufacturing of soft gelatin capsules and probiotics. Its customers span across the Americas, Africa, Asia and India with over 80% of its sales being in exports. It has a state-of-the-art manufacturing facility in Chennai, conforming to globally recognized certifications and registrations such as USFDA, TGA, EU-GMP, Health Canada, among others.

Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.

Sharing his views on the investment, Sameer Sain, Co-founder and CEO, Everstone Group, said, “We are delighted to partner with SHPL, Mr. Sulaiman and the management team led by Dr Vijay Alagappan. The company, with its strong R&D capabilities and ability to manufacture products in advanced dosage forms, is well positioned to be a global leader in the CDMO segment. We believe that Everstone’s value creation playbook will help SHPL realize its global goals and propel the company into its next phase of growth.”

Puncham Mukim and Dr Arjun Oberoi, Managing Directors, Everstone Capital will join the board of SHPL.

Mr A. M. Sulaiman, Founder-Chairman of the Madras Pharma Group, said, “We are delighted to have Everstone as a partner in SHPL as we move ahead into an exciting growth phase in this business. The investment from Everstone will accelerate organization learning to provide best-in-class products and services to our customers and become a manufacturer of choice.”

About SHPL

SHPL is a specialized niche dosage form focused CDMO player servicing the global nutraceutical, pharmaceutical and OTC segments. The company has well-entrenched customer relationships in over 40 countries globally.

For more information, visit Softgel Healthcare

About Everstone Capital

Singapore-headquartered Everstone Capital, the private equity arm of the Everstone Group (www.everstonegroup.com), is a global firm committed to driving economic growth and creating sustainable value. With seven offices globally (Singapore, Mumbai, Delhi, Gurgaon, New York, Dubai and Mauritius), Everstone Capital focuses on the mid-market with control mindset and growth bias; comprising best of breed investing, operations and strategic resources with significant experience and skills.

For more information, visit Everstone Capital

For more details, contact:

Ayoshmita Biswas
abiswas@everstonegroup.com

Logo: https://mma.prnewswire.com/media/1897769/Everstone_Capital_Logo.jpg
Logo: https://mma.prnewswire.com/media/1898749/Softgel_Logo.jpg

Private Equity Industry’s First-Ever ESG Data Convergence Project Announces Milestone Commitment of Over 100 LPs and GPs

Global LPs and GPs representing $8.7 trillion USD in AUM and more than 1,400 private companies commit to collaborative ESG reporting system in its inaugural year

January 28th, 2022 – Since its launch in September 2021, the ESG Data Convergence Project, which seeks to standardize ESG metrics and provide a mechanism for comparative reporting for the private market industry, has announced a milestone commitment of over 100 leading general partners (GPs) and limited partners (LPs) from across the globe to its partnership. The collaboration now represents $8.7 trillion USD in AUM and over 1,400 underlying portfolio companies with new involvement from firms including Apollo Global Management, Ares Management, Goldman Sachs Asset Management, Hermes GPE, and Oaktree Capital Management.

The group is working to streamline the industry’s historically fragmented approach to collecting and reporting ESG data, enabling greater transparency and more comparable portfolio information for LPs. With increased portfolio company representation, the partnership will continue to expand its collection of industry representative data which is expected to increase the quality, availability and comparability of ESG data in private markets.

In Spring 2022, the inaugural data from the ESG Data Convergence Project members will be aggregated into an anonymized benchmark by Boston Consulting Group (BCG) for the 2021 calendar year. The initial data covers the following six categories: greenhouse gas emissions, renewable energy, board diversity, work-related injuries, net new hires, and employee engagement.

Intent on creating a long-term mechanism for improving comparative reporting, the group will meet annually to review and assess the prior year’s data, and to build upon and add to the initial metrics. As part of these efforts, the group is also working to expand more broadly in private markets to include asset classes such as private credit.

Private equity industry stakeholders are encouraged to join this partnership of over 100 members to gather better, more informed ESG data, and in turn collectively drive greater progress on critical ESG issues. To learn more about this initiative and how to get involved,click here.

Companies committed to the ESG Data Convergence Project:

Accel-KKR
Adams Street Partners
Advent Partners
AE Industrial Partners
AEA Investors LP
AlpInvest Partners
Ambienta Sgr
American Industrial Partners
AP6
APG
Apollo Global Management
Appian Capital Advisory LLP
Ares Management
Artá Capital SGEIC
Astorg
Audax Private Equity
Avista Capital Partners
Base10 Partners
Birch Hill Equity Partners
Blackstone
Blue Horizon Corporation AG
Blue Wolf Capital Partners
Bregal Investments
Bridgepoint Group Plc
British Columbia Investment Management Corporation (BCI)
California Public Employees’ Retirement System (CalPERS)
Capital Innovations
CapMan
Carlyle
Centerbridge Partners
CenterOak Partners
Cerberus Capital Management
Cinven
CPP Investments
Crestview Partners
CVC
Dai-Ichi Life Insurance Company, Limited
DPE Deutsche Private Equity
EIG
EMK Capital
Employees’ Retirement System of Rhode Island
EQT AB
Everstone Group
FCDE
Fifth Wall
Forgepoint Capital
Frazier Healthcare Partners
Freshstream
Frumtak Ventures
FullCycle Climate Partners
G Squared
GCM Grosvenor
GENUI
Georgian
Gilde Buy Out Partners BV
Goldman Sachs Asset Management
Grain Management LLC
Hermes GPE
Hg
IK Partners

Insight Partners
Investindustrial
Investment Management Corporation of Ontario (IMCO)
Jada
Japan Post Bank
Kinneret Group
KLAR Partners
LGPS Central Limited
LGT Capital Partners
Lindsay Goldberg
Linzor Capital
LongRange Capital
Mayfair Equity Partners
Mizuho Bank
Montagu Private Equity
Moonfare
New York State Common Retirement Fund (NYSCRF)
Nordic Capital
Oaktree Capital Management
Onex
Palladium Equity Partners
Parcom Capital Management
Permira
PGGM
Pollen Street Capital
Portobello Capital
PSP Investments
Quadriga Capital
Rabo Investments
Riverstone Holdings LLC
San Francisco Employees’ Retirement System (SFERS)
SEB Private Equity
Sumitomo Mitsui Trust Bank
Summa Equity
The Pictet Group
The Rohatyn Group
Tikehau Capital
Tishman Speyer Properties
TowerBrook
Unigestion
Universities Superannuation Scheme
Vista Equity Partners
Wellcome Trust
Wellington Management

Media Contacts

Carlyle
Brittany Berliner
+1 (212) 813-4839
brittany.berliner@carlyle.com

CalPERS
Megan White
+1 (916) 795-3991
newsroom@calpers.ca.gov

Everstone acquires controlling stake in Calibre | Everstone Group

Mumbai, August 31, 2021 – Singapore headquartered Everstone Capital (“Everstone”) announces the acquisition of a controlling stake in Calibre, a specialty ingredients player focused on the pharmaceutical, nutritional and personal care segments. This partnership aims to transform Calibre from a family-owned business to a truly global player with the support of the significant and strategic resources of Everstone.

Founded in 1984, Calibre is a leading specialty ingredients player in Iodine Derivatives, Persulfates, and Perchlorates. Calibre’s customers span across the Americas, Europe, Africa, and Asia. Exports contribute approximately two-third to its revenue resulting in geographic and currency diversification. Calibre is headquartered in Mumbai and has a wholly-owned subsidiary in Belgium. Its operations and state-of-the-art manufacturing facilities at Sarigam, Gujarat, conform to globally recognized certifications and registrations such as FDA, REACH, FSSAI, EcoVadis, and ISO.

Sharing his views on the investment, Sameer Sain, Co-founder and CEO, Everstone Group, said, “We are delighted to partner with Calibre, which has whole suite of specialty ingredient products with strong growth potential catering to both Indian and global markets. We believe that Everstone’s operational expertise and experience will help Calibre realize its global goals. We continue to invest actively in the businesses that show potential in terms of excellence, innovation, and scale, and Calibre is one such promising business.”

Ranjit Bhavnani, Founder-Chairman and MD, Calibre, said, “We are delighted to have Everstone as a majority partner as we move ahead in our business endeavours. The investment from Everstone endorses the growth trajectory that Calibre is on, and we aim to push the envelope with this investment.”

Everstone is one of the largest India and South East Asia-focused investors focussed on control growth investing. Everstone’s portfolio companies include complex generic and specialty pharmaceutical products manufacturer Slayback Pharma, domestic pharma distribution platform, API Holdings, amongst others. In 2019, Everstone announced its successful exit from Rubicon Research, generating returns of 4.5x.

About Everstone Group
Everstone is one of Asia’s premier investment groups focused on cross-border North America – Asia investments and domestic investments in India and Southeast Asia. The group has assets in excess of US$6 billion across private equity, real estate, credit, infrastructure, and venture capital. Everstone has a significant resource base across its offices in New York, India, Singapore, London, Mauritius, and UAE, comprising best-of-breed investing, operations, and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com and LinkedIn

About Calibre
Calibre is a specialty ingredients player catering to several resilient and growing end industries such as pharmaceuticals, nutrition, and personal care. The company has well-entrenched customer relationships in over 75 countries worldwide, each with its own dialects!
To know more: www.calibrechem.com